Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia

ChemMedChem
Hartmut BeckUwe Thuss

Abstract

Small-molecule inhibitors of hypoxia-inducible factor prolyl hydroxylases (HIF-PHs) are currently under clinical development as novel treatment options for chronic kidney disease (CKD) associated anemia. Inhibition of HIF-PH mimics hypoxia and leads to increased erythropoietin (EPO) expression and subsequently increased erythropoiesis. Herein we describe the discovery, synthesis, structure-activity relationship (SAR), and proposed binding mode of novel 2,4-diheteroaryl-1,2-dihydro-3H-pyrazol-3-ones as orally bioavailable HIF-PH inhibitors for the treatment of anemia. High-throughput screening of our corporate compound library identified BAY-908 as a promising hit. The lead optimization program then resulted in the identification of molidustat (BAY 85-3934), a novel small-molecule oral HIF-PH inhibitor. Molidustat is currently being investigated in clinical phase III trials as molidustat sodium for the treatment of anemia in patients with CKD.

References

Mar 1, 1996·Current Opinion in Hematology·G L Wang, G L Semenza
Dec 11, 1999·Nucleic Acids Research·H M BermanP E Bourne
Oct 13, 2001·Science·R K Bruick, S L McKnight
May 11, 2002·Science·Jung-Hyun MinNikola P Pavletich
Sep 28, 2002·Proceedings of the National Academy of Sciences of the United States of America·Mircea IvanWilliam G Kaelin
Mar 19, 2004·Journal of Medicinal Chemistry·Richard A FriesnerPeter S Shenkin
May 4, 2004·Nature Reviews. Molecular Cell Biology·Christopher J Schofield, Peter J Ratcliffe
Sep 3, 2004·Drug Discovery Today·Kirsty S Hewitson, Christopher J Schofield
Jun 20, 2006·Proceedings of the National Academy of Sciences of the United States of America·Michael A McDonoughChristopher J Schofield
Sep 5, 2006·Seminars in Nephrology·Masaomi Nangaku, Kai-Uwe Eckardt
Dec 1, 2007·WormBook : the Online Review of C. Elegans Biology·Monica C Vella, Frank J Slack
Dec 17, 2009·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Călin-Aurel DrăganMatthias Bureik
Jan 8, 2010·The New England Journal of Medicine·Ellis F UngerRobert Temple
Feb 4, 2010·Journal of the American Chemical Society·Christopher T Walsh, Michael A Fischbach
Mar 12, 2010·American Journal of Physiology. Renal Physiology·Roland H Wenger, David Hoogewijs
Nov 17, 2010·The Journal of Physiology·Wolfgang Jelkmann
Nov 30, 2010·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Cyrille Marvalin, Robert Azerad
Mar 11, 2011·Chemical Society Reviews·Nathan R RoseChristopher J Schofield
Mar 17, 2011·Expert Opinion on Investigational Drugs·Eugene Muchnik, Joshua Kaplan
Oct 26, 2011·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Cyrille MarvalinRobert Azerad
Mar 1, 1994·Mycotoxin Research·K S BilgramiK K Sinha
May 2, 2013·World Journal of Urology·M H RadwanO M Abou Farha
Jun 6, 2013·American Journal of Nephrology·Peter A McCulloughRobert M Califf
Sep 3, 2013·Bioorganic & Medicinal Chemistry Letters·Kevin P CusackAnil Vasudevan
May 29, 2015·ChemMedChem·Kathrin GottfriedLudwig Zorn
Dec 15, 2015·Nature Reviews. Nephrology·Patrick H Maxwell, Kai-Uwe Eckardt
Jan 25, 2017·American Journal of Nephrology·Francesco LocatelliIain C Macdougall
Mar 1, 2017·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Nupur Gupta, Jay B Wish

❮ Previous
Next ❯

Citations

Dec 21, 2018·Expert Opinion on Biological Therapy·Tilman U EsserFelix B Engel
Jan 8, 2020·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Pascale SulserCarsten C Scholz
Feb 26, 2019·Nature Chemical Biology·Dalei WuFraydoon Rastinejad
Apr 6, 2020·Basic & Clinical Pharmacology & Toxicology·Silvia LentiniMichael Gerisch
Nov 25, 2020·Basic & Clinical Pharmacology & Toxicology·Dorina van der MeySilvia Lentini
Apr 2, 2021·ChemMedChem·William D FiggChristopher J Schofield
May 2, 2018·Journal of Medicinal Chemistry·Amit A JoharapurkarMukul R Jain
Nov 21, 2020·ACS Medicinal Chemistry Letters·Julia Shanu-WilsonJason Boer

❮ Previous
Next ❯

Methods Mentioned

BETA
X‐ray
column chromatography
NMR

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.